Guildford, UK, 8 September 2010: ReNeuron Group plc (LSE: RENE.L) gives a trading update ahead of its 2010 Annual General Meeting which will take place today at 10.00am (BST) at the offices of Morrison & Foerster, City Point, One Ropemaker Street, London, EC2Y 9AW.

More…

Guildford, UK, 8 September 2010: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today’s 2010 Annual General Meeting were passed.

More…

Guildford, UK, 9 August 2010: ReNeuron Group plc (the “Company”) (LSE: RENE.L) announces that its Annual Report and Accounts for the year ended 31 March 2010 and the Notice of the 2010 Annual General Meeting (AGM) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com. 

More…

ReNeuron Group plc (AIM: RENE) (the ‘Company’), a leading, UK-based stem cell business, is pleased to announce that it will host an investor evening on 27 July 2010

More…

Guildford, UK, 12 July 2010: ReNeuron Group plc (LSE: RENE.L) today announces important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage.  The results of these studies will be presented in two posters1 at the UK National Stem Cell Network Annual Scientific Conference, taking place on 12 – 14 July, 2010 at the University of Nottingham, East Midlands Conference Centre, Nottingham, UK. 

More…

Reneuron announces preliminary results for the year ending 31 March 2010.

More…

ReNeuron Group plc (AIM: RENE.L), a leading UK-based stem cell company, today announces that it will report its preliminary results for the 12 months ended 31 March 2010 on Tuesday 29 June 2010.

More…

Guildford, UK, 29 April 2010: ReNeuron Group plc (LSE: RENE.L) today announces that positive data from a number of new pre-clinical studies using its CTX stem cell line for stroke will be presented in an oral presentation1 and posters2 at the 17th Annual Conference of the American Society for Neural Therapy and Repair, taking place on April 29 to May 1, 2010 at the Sheraton Sand Key Resort, Clearwater Beach, Florida, USA.  The studies were conducted by Dr Mike Modo, Senior Lecturer in Stem Cell Imaging at the Centre for the Cellular Basis of Behaviour, King’s College London, in collaboration with colleagues at the Centre for Biomolecular Sciences, University of Nottingham, UK and the Centre for Biomedical Research and Department of Biological Sciences, Carnegie Mellon University, Pennsylvania, USA.

More…

Guildford, UK, 22 March 2010: ReNeuron Group plc (LSE: RENE.L) is pleased to learn that it has been cited as a UK-based world leader in regenerative medicine in a new publication by the UK Government.  The “Best of British” publication, produced by the Department for Business Innovation and Skills (BIS), showcases in a series of sector case studies the business sectors in which the UK leads on innovation, enterprise and technology.  These are the sectors from which future UK economic growth and jobs are expected to be generated and include life sciences, digital communications and renewable energy, among others. 

More…

Guildford, UK, 15 March 2010: ReNeuron Group plc (LSE: RENE.L) announced on 22 February 2010 that it had raised approximately £4.7 million, before expenses, from existing and new institutional and qualifying individual shareholders via a placing (the “Placing”) of 94,400,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up, at a price of 5 pence per Ordinary Share (the “Placing Shares”).

To enable certain placees to take advantage of Venture Capital Trust and Enterprise Investment Scheme tax treatment, the Placing comprises two closings and admissions of Ordinary Shares to trading on AIM. On 12 March 2010 ReNeuron Group Plc announced that shareholder approval for the Placing had been received and that 16,800,000 of the Placing Shares were allotted on first closing of the Placing.

Today ReNeuron Group Plc announces that the second closing and admission of 77,600,000 of the Placing Shares (the “Second Admission Shares”) is expected to occur on 19 March 2010. Pursuant to the second closing and admission, the Second Admission Shares were today allotted, subject only to admission. Application for admission of the Second Admission Shares to trading on AIM has been made.

Following second closing and admission, the issued share capital of ReNeuron Group plc shall comprise 437,709,571 Ordinary Shares. The Company holds no shares in treasury. Therefore, the total number of voting rights in the Company is 437,709,571. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority’s Disclosure and Transparency Rules.

Notes to editors

ReNeuron is a leading, UK-based stem cell company. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has regulatory approval for a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. Patient recruitment for this trial will commence shortly. The Company is also developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

Daniel Stewart & Company plc and Matrix Corporate Capital LLP are each authorised and regulated by the Financial Services Authority, and are each acting for the Company and for no-one else in connection with the Placing and will not be responsible to anyone other than the Company for providing the protections afforded to their respective customers or for affording advice in relation to the matters referred to herein. This announcement has been issued by, and is the sole responsibility of, the Company. Neither Daniel Stewart & Company plc nor Matrix Corporate Capital LLP accepts any liability whatsoever for the accuracy or opinions contained in this announcement (or for the omission of any material information) and neither Daniel Stewart & Company plc nor Matrix Corporate Capital LLP shall be responsible for the contents of this announcement.

Further information

Enquiries
Michael Hunt, Chief Executive Officer
ReNeuron Group plc+44 (0) 1483 302560
Jonathan Birt, Susan Quigley
Financial Dynamics+44 (0) 20 7831 3113

Simon Leathers, Emma Earl
Daniel Stewart & Company plc +44 (0) 20 7776 6550
Alastair Stratton, Steve Quinn
Matrix Corporate Capital LLP+44 (0) 20 3206 7000